Experts discuss Artificial Intelligence at the U.S. Space and Rocket Center Symposium
That's no different here in North Alabama as the U.S. Space and Rocket Center hosted its second AI Symposium.
Over 80 dogs taken to Lauderdale County shelter as part of cruelty investigation
'We all have a role to play in figuring out where we want AI to go and what we're comfortable with, and, crucially, what we're not comfortable with,' Andrew Miller said.
He is a clinical lecturer of law from Yale Law School. Miller said we will soon see AI in the courtroom.
'So whether it's the judge side or the actual lawyer side, you're going to see AI playing a role throughout the legal system, and it's important that we decide again where we like that, where we don't, and how to regulate it,' he said.
City council approves bid to demolish long-standing Florence parking deck
When it comes to the fear of artificial intelligence replacing jobs, he wants people to think about what they can bring to the workforce as humans.
'I would encourage people who are worried about this not to change their minds, but to use this as an opportunity to, to think about the role they play, not just in their companies, but in their communities and where they, as humans really add value,' he said.
Kristianna Berger is a student at the Alabama School of Cyber Technology and Engineering. She was one of many who asked great questions.
'Learning how it's used in law and also how does that affect the workforce?' she asked. 'How is it going to, you know, we say replace our jobs…. is that really true and how is it going to affect our futures?'
While our technology has come miles, even Miller said there is still a long way to go before we perfect Artificial Intelligence and all the questions it brings.
'The legal questions of how the responsibility works are really complicated and deserve serious, sustained attention,' Miller said. 'I think it'll take a little while before we figured out what we think the right answer is.'
The symposium will continue through Thursday and walk-in registration is available if anyone would like to attend.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
10 hours ago
- Associated Press
Researchers awarded $10.5 million to study use of AI in addressing cardiovascular disease
( NewMediaWire ) - July 24, 2025 - DALLAS — Research teams from Kaiser Permanente Division of Research in Pleasanton, California, and the University of Michigan in Ann Arbor have been awarded a total of $10.5 million to conduct research projects that explore ways to use artificial intelligence (AI) to accelerate and improve screening and treatment for cardiovascular disease, the leading cause of death in the U.S. The projects are funded through a special research grant from the American Heart Association, a global force changing the future of health for all. 'AI was once relegated to the realm of science fiction; however, it's quickly becoming a part of everyday life for all of us. The American Heart Association has been a leader in cardiovascular science and research for more than a century, and we recognize the importance of learning how we can harness this revolutionary tool to improve health for people everywhere,' said Stacey E. Rosen, M.D., FAHA, American Heart Association volunteer president, senior vice president of Women's Health and executive director of the Katz Institute for Women's Health of Northwell Health in New York City. 'I'm very excited about these two new research projects we are funding and look forward to the knowledge we may gain for how AI technology can empower health care professionals to make informed decisions and, ultimately, improve health outcomes and save lives.' The awards, which started July 1, 2025, will fund the following research: Kaiser Permanente Division of Research Center: Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (Team SCOUT-Echo-AI) – This multi-disciplinary research team is led by David Ouyang, M.D., a research scientist at the Kaiser Permanente Northern California Division of Research and a non-invasive cardiologist at Kaiser Permanente Santa Clara Medical Center. The team will look at ways to use AI to expand the usefulness of heart ultrasounds, or echocardiograms, which are common, inexpensive, portable tests that don't use radiation. While doctors currently use ultrasounds to check the heart, these scans can also show nearby organs like the liver and kidneys. Although previous research has found that conditions impacting the kidneys and liver can lead to an increased risk of complications related to cardiovascular disease, cardiologists aren't trained to look for problems in these other organs. The team will conduct a prospective multi-center clinical trial to evaluate whether AI technology can be used to detect early signs of kidney and liver disease on heart ultrasounds. They'll test their method in four different health care systems (Stanford Health Care, Cedars-Sinai, Massachusetts General Brigham and Kaiser Permanente Northern California) to find the best ways to alert doctors and patients to these findings. Early diagnosis of kidney and liver disease can improve the chances of getting treatment for these conditions, as well as reduce the complications that impact cardiovascular disease. Early diagnosis and treatment of kidney and liver disease is increasingly important because the prevalence of cardiovascular, kidney and liver disease are all on the rise, as referenced in several reports from the American Heart Association: University of Michigan: INSIGHT-CPR: Integrated Neural networks and wearable Sensor to Instantaneously Guide Hemodynamic-direcTed CPR – This research team is led by Cindy Hsu, M.D., Ph.D., M.S., division chief of critical care in the University of Michigan Department of Emergency Medicine. The team will explore whether AI can improve the way CPR is delivered to people who experience sudden cardiac arrest. Sudden cardiac arrest is a life-threatening medical emergency that happens when the heart suddenly stops beating. Immediately beginning CPR with chest compressions can help save lives by getting blood circulating through the heart and the rest of the body. Most patients need many minutes of CPR to sustain the body until the heart's normal function resumes. The longer it takes for the heart to resume normal activity, the worse outcomes they have. If CPR was personalized based on each patient's specific needs, it could sustain bodily functions more effectively. However, emergency responders can't always measure how effective CPR is because blood pressure measurements require inserting catheters and are affected by the recoil of the patient's chest wall during CPR. The research team has used AI to create an innovative algorithm integrated with a noninvasive wearable sensor to accurately measure blood pressure, even during CPR. This technology can help doctors and emergency responders see, in real time, how well blood is flowing to the arterial circulation, so they can adjust their techniques and medications to give patients the best chance of survival. In this project, the team will further develop and test this algorithm and sensor with plans to commercialize the tool so that it is widely available to potentially save more lives. According to the American Heart Association: 'While artificial intelligence and machine-learning may seem like the buzz phrases of the day, pioneering research has long been an essential element of the American Heart Association's work, and these new research grants are not our first foray into this space,' Rosen said. 'We've been instrumental in bringing cutting-edge technology to millions of scientists across the globe through our Precision Medicine Platform launched nearly a decade ago, and we will continue to drive those projects that can add to the body of science that supports our lifesaving mission to be a relentless force for a world of longer, healthier lives.' Funding scientific research and discovery through initiatives like these grants is a cornerstone of the American Heart Association's lifesaving mission. The Association has funded more than $6 billion in cardiovascular, cerebrovascular and brain health research since 1949, making it the single largest nonprofit, non-government supporter of heart and brain health research in the U.S. New knowledge resulting from this funding continues to save lives and directly impact millions of people in every corner of the U.S. and around the world. ### About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on Facebook, X or by calling 1-800-AHA-USA1. For Media Inquiries: Cathy Lewis, [email protected] For Public Inquiries: 1-800-AHA-USA1 (242-8721) and
Business Wire
13 hours ago
- Business Wire
Elation Survey Finds Nearly 40% of Primary Care Physicians Use AI-powered Tools for Daily Clinical Documentation
SAN FRANCISCO--(BUSINESS WIRE)-- Elation Health, the clinical-first technology company powering innovation in primary care, today announced the results of its latest AI in Primary Care survey of 291 primary care physicians, focused on the current sentiments, adoption patterns, critical concerns (defects), key behavioral insights (learnings), and explicit user desires (requests) regarding the integration of Artificial Intelligence (AI) in primary care workflows. The analysis reveals 39.3% use AI-powered tools daily, specifically for clinical documentation. The survey also revealed that clinicians have a clear hierarchy of needs when it comes to AI, with fundamental performance factors at the top of that hierarchy. With 59% of respondents in agreement, accuracy and reliability ranked as the most important factor when evaluating AI tools. Seamless workflow integration and ease of use followed at 22%, while efficiency and time savings (ROI) came in at 13%, and cost affordability at 6% (see Table 1). Table 1: Most Important Factors in Choosing an AI Tool 'Our survey confirms what we already suspected: clinicians are cautiously optimistic about AI's potential, but they're looking for thoughtful, trustworthy, affordable solutions that truly fit the realities of primary care,' said Sara Pastoor, MD, MHA, FAAFP, and director of primary care advancement for Elation Health. 'At Elation, we're applying AI in ways that are context-aware, and fit naturally into clinical and operational workflows to enable high-quality care hand in hand with long-term financial success.' While the survey also affirmed the general attitude towards AI in clinical settings is predominantly positive, a notable segment remains neutral or skeptical. Although a combined 59% of respondents rate their sentiment as "Positive" or "Very Positive," 24% of respondents were 'Neutral' in their sentiments about AI. This sizable group appears to be open to AI advancements but may be likely waiting for clear evidence of its value, reliability, and ease of use before fully embracing it. These findings reinforce how Elation approaches research and development with Elation's Innovation Labs that leverage a dynamic, interactive product development and testing framework to allow it to work shoulder-to-shoulder with clinicians and staff through design cycles, usability testing, and continuous in-product feedback. This ensures Elation is developing AI in ways that clinicians trust and find valuable. Elation Health's clinical-first approach to AI is distinguished by continuous, hands-on collaboration with primary care clinicians throughout the Elation Labs development process. Every new AI capability is shaped directly by clinician feedback, gathered through design cycles, usability testing, and ongoing in-product input. Elation's iterative, transparent partnership with customers ensures that its AI features are clinically relevant, trustworthy, and seamlessly integrated into daily workflows, empowering clinicians while keeping the focus firmly on patient care. The survey was conducted with 291 independent primary care clinicians who are current Elation Health customers. For more on the results from Elation's State of AI in Primary Care Clinical Practice survey, visit here. To join Elation's product developers for a live, interactive webinar to explore how ethical, clinician-designed AI embedded within the EHR is transforming primary care by reducing burnout, improving care quality, and empowering both clinicians and patients: register here. About Elation Elation Health is the clinical-first AI platform for primary care success. Trusted by over 36,000 clinicians and 20 million patients, Elation's EHR and billing solutions combine proven clinical workflows with responsible, predictive AI - purpose built for primary care. The company's clinical-first approach puts physicians at the center, delivering trusted, transparent innovation that saves time and sustains meaningful patient relationships. Elation Health is recognized as Best in KLAS for its commitment to excellence in primary care technology. Learn more at and on LinkedIn.
Yahoo
14 hours ago
- Yahoo
The Figma IPO Is Coming -- but Can It Justify Its Valuation?
Key Points IPOs have been hot this year, with most of the big ones generating strong returns in just a few months. Figma makes building design and user interface projects much more collaborative, and it plans to integrate many artificial intelligence tools. The company is targeting a valuation in the range of $13.6 billion to $16.5 billion fully diluted. These 10 stocks could mint the next wave of millionaires › Investors who have participated in initial public offerings (IPOs) like CoreWeave, Circle Internet Group, and Chime Financial have done quite well this year, which is why it's no surprise to see big hype around another incoming IPO, Figma. Positioned as the Google Sheets of the design and user interface world, Figma allows multiple people to collaborate on design projects, although the company has really morphed into a way for companies to turn ideas into software. Figma sees immense potential to integrate artificial intelligence into its business and even owns crypto as well. Figma is planning to IPO at a valuation in the range of $13.6 billion to $16.5 billion on a fully diluted basis. But does the company's exciting business justify this large valuation? A real game changer in design Brown University alums Dylan Field and Evan Wallace launched Figma in 2012, seeking a way to make the design process more collaborative from a technological perspective. They would eventually create a platform that allowed multiple people to work on design projects through the power of the web but also with high-quality graphics. Image source: Getty Images. As technology advanced, the platform did as well, particularly with the release of Dev Mode in 2023, which allowed designers to translate their concepts into code without changing the design file. This ultimately made it easier for designers and coders to work together. Products like this have gained traction, and today, Figma has 13 million unique monthly users, two-thirds of whom aren't designers. Roughly 95% of companies in the Fortune 500 use Figma, so the company is not reliant on a few core customers. Additionally, Figma sees immense potential to integrate more artificial intelligence (AI) tools into its business. Figma Make already lets users convert a conversational prompt into a working prototype in just minutes. The company believes it stands to benefit from the growth of AI, projecting that there will be 1 billion new apps in the world by 2028, many of which will come to Figma for their branding and user interface. Do the financials justify the valuation? The big question with all of these new and exciting IPOs is: Are they too hot out of the gate, or can their growth really justify the valuation? Figma is looking to raise $1 billion and list shares at $25 to $28, giving it a valuation of $13.6 billion at the high end of that range. However, Barron's estimates that the valuation could really be as high as $16.5 billion on a fully diluted basis.
